Citations (247)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (42)
Asef Azad, Ümmü Rana Gökmen, Hilmi Uysal, Sadi Köksoy, Uğur Bilge & Ayşe Esra Manguoğlu. (2023) Autophagy dysregulation plays a crucial role in regulatory T-cell loss and neuroinflammation in amyotrophic lateral sclerosis (ALS). Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 0:0, pages 1-9.
Read now
Read now
Gary L. Pattee, Angela Genge, Philippe Couratier, Christian Lunetta, Gen Sobue, Masashi Aoki, Hiide Yoshino, Carlayne E. Jackson, James Wymer, Alejandro Salah & Sally Nelson. (2023) Oral Edaravone – Introducing a Flexible Treatment Option for Amyotrophic Lateral Sclerosis. Expert Review of Neurotherapeutics 0:0, pages 1-8.
Read now
Read now
Jeremy M. Shefner, Ammar Al-Chalabi, Jinsy A. Andrews, Adriano Chio, Mamede De Carvalho, Bettina M. Cockroft, Philippe Corcia, Philippe Couratier, Merit E. Cudkowicz, Angela Genge, Orla Hardiman, Terry Heiman-Patterson, Robert D. Henderson, Caroline Ingre, Carlayne E. Jackson, Wendy Johnston, Noah Lechtzin, Albert Ludolph, Nicholas J. Maragakis, Timothy M. Miller, Jesus S. Mora Pardina, Susanne Petri, Zachary Simmons, Leonard H. Van Den Berg, Lorne Zinman, Stuart Kupfer, Fady I. Malik, Lisa Meng, Tyrell J. Simkins, Jenny Wei, Andrew A. Wolff & Stacy A. Rudnicki. (2023) COURAGE-ALS: a randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of success. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 24:5-6, pages 523-534.
Read now
Read now
Hee Jo Han, Ha Young Shin, Young-Chul Choi, Seung Min Kim & Seung Woo Kim. (2022) Serum uric acid level predicts the progression of amyotrophic lateral sclerosis following treatment with edaravone. Redox Report 27:1, pages 79-84.
Read now
Read now
Benjamin Rix Brooks, Erik P. Pioro, Danielle Beaulieu, Albert A. Taylor, Mark Schactman, Mike Keymer, Wendy Agnese, Johnna Perdrizet, Stephen Apple & David L. Ennist. (2022) Evidence for generalizability of edaravone efficacy using a novel machine learning risk-based subgroup analysis tool. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 23:1-2, pages 49-57.
Read now
Read now
Pamela A. McCombe, Fleur C Garton, Matthew Katz, Naomi R Wray & Robert D Henderson. (2020) What do we know about the variability in survival of patients with amyotrophic lateral sclerosis?. Expert Review of Neurotherapeutics 20:9, pages 921-941.
Read now
Read now
R Hergesheimer, D Lanznaster, P Vourc’h, Cr Andres, Se Bakkouche, S Beltran, H Blasco, P Corcia & P Couratier. (2020) Advances in disease-modifying pharmacotherapies for the treatment of amyotrophic lateral sclerosis. Expert Opinion on Pharmacotherapy 21:9, pages 1103-1110.
Read now
Read now
Andrea Barp, Francesca Gerardi, Andrea Lizio, Valeria Ada Sansone & Christian Lunetta. (2020) Emerging Drugs for the Treatment of Amyotrophic Lateral Sclerosis: A Focus on Recent Phase 2 Trials. Expert Opinion on Emerging Drugs 25:2, pages 145-164.
Read now
Read now
Nathalie Braun, Eric A. Macklin, Ervin Sinani, Alexander Sherman & Markus Weber. (2020) The revised El Escorial criteria “clinically probable laboratory supported ALS”—once a promising now a superfluous category?. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 21:1-2, pages 24-28.
Read now
Read now
Hideyuki Sawada. (2019) Considerations for pharmacotherapy use in patients with amyotrophic lateral sclerosis: the earlier it starts, the better the results. Expert Opinion on Pharmacotherapy 20:14, pages 1671-1674.
Read now
Read now
Joseph M. Palumbo, Jean Hubble, Stephen Apple, Koji Takei, Kikumi Tsuda, Shawn Liu, Jeffrey Zhang & Wendy Agnese. (2019) Post-hoc analyses of the edaravone clinical trials Study 16 and Study 19: a step toward more efficient clinical trial designs in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 20:5-6, pages 421-431.
Read now
Read now
Alon Abraham, Beatrice Nefussy, Yaara Fainmesser, Yoram Ebrahimi, Arnon Karni & Vivian E. Drory. (2019) Early post-marketing experience with edaravone in an unselected group of patients with ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 20:3-4, pages 260-263.
Read now
Read now
Francesca Palese, Arianna Sartori, Giancarlo Logroscino & Federica Edith Pisa. (2019) Predictors of diagnostic delay in amyotrophic lateral sclerosis: a cohort study based on administrative and electronic medical records data. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 20:3-4, pages 176-185.
Read now
Read now
Hiide Yoshino. (2019) Edaravone for the treatment of amyotrophic lateral sclerosis. Expert Review of Neurotherapeutics 19:3, pages 185-193.
Read now
Read now
. (2018) Theme 13 Clinical management and support. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 19:sup1, pages 353-374.
Read now
Read now
John Turnbull. (2018) Is edaravone harmful? (A placebo is not a control). Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 19:7-8, pages 477-482.
Read now
Read now
Nimish J. Thakore, Brittany R. Lapin, Tyler G. Kinzy & Erik P. Pioro. (2018) Deconstructing progression of amyotrophic lateral sclerosis in stages: a Markov modeling approach. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 19:7-8, pages 483-494.
Read now
Read now
Marion C. Hogg, Luise Halang, Ina Woods, Karen S. Coughlan & Jochen H. M. PREHN. (2018) Riluzole does not improve lifespan or motor function in three ALS mouse models. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 19:5-6, pages 438-445.
Read now
Read now
Crystal Jing Jing Yeo & Zachary Simmons. (2018) Discussing edaravone with the ALS patient: an ethical framework from a U.S. perspective. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 19:3-4, pages 167-172.
Read now
Read now
Carmel Armon. (2018) Ethics of clinical research in patients with ALS: is there a risk of exploitation?. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 19:3-4, pages 161-166.
Read now
Read now
Shyuan T Ngo, Jia D Mi, Robert D Henderson, Pamela A McCombe & Frederik J Steyn. (2017) Exploring targets and therapies for amyotrophic lateral sclerosis: current insights into dietary interventions. Degenerative Neurological and Neuromuscular Disease 7, pages 95-108.
Read now
Read now
Koji Takei, Kikumi Tsuda, Fumihiro Takahashi & Joseph Palumbo. (2017) Post-hoc analysis of open-label extension period of study MCI186-19 in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 18:sup1, pages 64-70.
Read now
Read now
. (2017) Open-label 24-week extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 18:sup1, pages 55-63.
Read now
Read now
. (2017) A post-hoc subgroup analysis of outcomes in the first phase III clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 18:sup1, pages 11-19.
Read now
Read now
Alexander Kalin, Elvia Medina-Paraiso, Kaoru Ishizaki, Alex Kim, Yannong Zhang, Takanori Saita & Masahiko Wasaki. (2017) A safety analysis of edaravone (MCI-186) during the first six cycles (24 weeks) of amyotrophic lateral sclerosis (ALS) therapy from the double-blind period in three randomized, placebo-controlled studies. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 18:sup1, pages 71-79.
Read now
Read now
. (2017) Exploratory double-blind, parallel-group, placebo-controlled extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 18:sup1, pages 20-31.
Read now
Read now
Nicholas J. Maragakis. (2017) What can we learn from the edaravone development program for ALS?. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 18:sup1, pages 98-103.
Read now
Read now
Koji Takei, Kikumi Tsuda, Fumihiro Takahashi, Manabu Hirai & Joseph Palumbo. (2017) An assessment of treatment guidelines, clinical practices, demographics, and progression of disease among patients with amyotrophic lateral sclerosis in Japan, the United States, and Europe. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 18:sup1, pages 88-97.
Read now
Read now
Koji Takei, Fumihiro Takahashi, Shawn Liu, Kikumi Tsuda & Joseph Palumbo. (2017) Post-hoc analysis of randomised, placebo-controlled, double-blind study (MCI186-19) of edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 18:sup1, pages 49-54.
Read now
Read now
Fumihiro Takahashi, Koji Takei, Kikumi Tsuda & Joseph Palumbo. (2017) Post-hoc analysis of MCI186-17, the extension study to MCI186-16, the confirmatory double-blind, parallel-group, placebo-controlled study of edaravone in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 18:sup1, pages 32-39.
Read now
Read now
. (2017) Exploratory double-blind, parallel-group, placebo-controlled study of edaravone (MCI-186) in amyotrophic lateral sclerosis (Japan ALS severity classification: Grade 3, requiring assistance for eating, excretion or ambulation). Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 18:sup1, pages 40-48.
Read now
Read now
Koji Takei, Kazutoshi Watanabe, Satoshi Yuki, Makoto Akimoto, Takeshi Sakata & Joseph Palumbo. (2017) Edaravone and its clinical development for amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 18:sup1, pages 5-10.
Read now
Read now
Yoshinobu Nakamaru, Shuji Kinoshita, Atsuhiro Kawaguchi, Koji Takei, Joseph Palumbo & Masayuki Suzuki. (2017) Pharmacokinetic profile of edaravone: a comparison between Japanese and Caucasian populations. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 18:sup1, pages 80-87.
Read now
Read now
Bello Hamidou, Benoit Marin, Geraldine Lautrette, Marie Nicol, William Camu, Philippe Corcia, Marie-Christine Arnes-Bes, Christine Tranchant, Pierre Clavelou, Didier Hannequin, Giroud Maurice, Katell Beauvais, Jean-Christophe Antoine, Véronique Danel-Brunaud, Fausto Viader, Pierre-Marie Preux & Philippe Couratier. (2017) Exploring the diagnosis delay and ALS functional impairment at diagnosis as relevant criteria for clinical trial enrolment*. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 18:7-8, pages 519-527.
Read now
Read now
Hideyuki Sawada. (2017) Clinical efficacy of edaravone for the treatment of amyotrophic lateral sclerosis. Expert Opinion on Pharmacotherapy 18:7, pages 735-738.
Read now
Read now
Yu-ichi Noto, Kazumoto Shibuya, Steve Vucic & Matthew C. Kiernan. (2016) Novel therapies in development that inhibit motor neuron hyperexcitability in amyotrophic lateral sclerosis. Expert Review of Neurotherapeutics 16:10, pages 1147-1154.
Read now
Read now
Rebecca Traub & Hiroshi Mitsumoto. (2016) Recent advances and opportunities for improving diagnosis of amyotrophic lateral sclerosis. Expert Opinion on Orphan Drugs 4:9, pages 907-915.
Read now
Read now
H Blasco, F Patin, CR Andres, P Corcia & PH Gordon. (2016) Amyotrophic Lateral Sclerosis, 2016: existing therapies and the ongoing search for neuroprotection. Expert Opinion on Pharmacotherapy 17:12, pages 1669-1682.
Read now
Read now
Verena C Haringer & Summer B Gibson. (2015) Amyotrophic lateral sclerosis: clinical perspectives. Orphan Drugs: Research and Reviews 5, pages 19-31.
Read now
Read now
Kazumoto Shibuya, Sonoko Misawa, Hideki Kimura, Yu-Ichi Noto, Yasunori Sato, Yukari Sekiguchi, Yuta Iwai, Satsuki Mitsuma, Minako Beppu, Keisuke Watanabe, Yumi Fujimaki, Yukiko Tsuji, Toshio Shimizu, Toshiki Mizuno, Masanori Nakagawa, Kyoko Sawaguchi, Hideki Hanaoka & Satoshi Kuwabara. (2015) A single blind randomized controlled clinical trial of mexiletine in amyotrophic lateral sclerosis: Efficacy and safety of sodium channel blocker phase II trial. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 16:5-6, pages 353-358.
Read now
Read now
Sabina Antonela Antoniu. (2015) Fresh from the designation pipeline: orphan drugs designated in the European Union (November – December 2014). Expert Opinion on Orphan Drugs 3:6, pages 719-725.
Read now
Read now
Muzammil Arif Din Abdul Jabbar, Ling Guo, Sonakshi Nag, Yang Guo, Zachary Simmons, Erik P. Pioro, Savitha Ramasamy & Crystal Jing Jing Yeo. Predicting amyotrophic lateral sclerosis (ALS) progression with machine learning. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 0:0, pages 1-14.
Read now
Read now
Articles from other publishers (205)
Daphne N. Weemering, Mark Midei, Peter Milner, Vidhya Gopalakrishnan, Anil Kumar, Andrew J. Dannenberg, Tommy M. Bunte, Juliette Foucher, Caroline Ingre, Viktorija Ķēniņa, Karin Rallmann, Leonard H. van den Berg & Ruben P. A. van Eijk. (2023)
A randomized, double‐blind, placebo‐controlled phase 2 study to assess safety, tolerability, and efficacy of
RT001
in patients with amyotrophic lateral sclerosis
. European Journal of Neurology 30:12, pages 3722-3731.
Crossref
Crossref
Mhoriam Ahmed, Charlotte Spicer, Jasmine Harley, J. Paul Taylor, Michael Hanna, Rickie Patani & Linda Greensmith. (2023) Amplifying the Heat Shock Response Ameliorates ALS and FTD Pathology in Mouse and Human Models. Molecular Neurobiology 60:12, pages 6896-6915.
Crossref
Crossref
Renjia Zhong, Michael T. Rua & Lan Wei‐LaPierre. (2023)
Targeting mitochondrial Ca
2+
uptake for the treatment of amyotrophic lateral sclerosis
. The Journal of Physiology.
Crossref
Crossref
Eleanor Roberts. (2023) A Review of Oral Fixed-Dose Sodium Phenylbutyrate and Ursodoxicoltaurine in People with Amyotrophic Lateral Sclerosis. EMJ Neurology, pages 2-12.
Crossref
Crossref
Gavin Lockard, Jonah Gordon, Samantha Schimmel, Bassel El Sayed, Molly Monsour, Svitlana Garbuzova‐Davis & Cesar V. Borlongan. (2023) Attenuation of amyotrophic lateral sclerosis via stem cell and extracellular vesicle therapy: An updated review. Neuroprotection.
Crossref
Crossref
Hidetoshi Shimizu, Yukiko Nishimura, Youichi Shiide, Makoto Akimoto, Makiko Yashiro, Masaki Ueda, Manabu Hirai, Hiide Yoshino, Tomohiko Mizutani, Kazuaki Kanai, Osamu Kano, Hideki Kimura, Hisakuni Sekino & Kimiko Ito. (2023) Pharmacokinetics of Edaravone Oral Suspension in Patients With Amyotrophic Lateral Sclerosis. Clinical Therapeutics.
Crossref
Crossref
Nicholas J. Maragakis, Mamede de Carvalho & Michael D. Weiss. (2023)
Therapeutic targeting of
ALS
pathways: Refocusing an incomplete picture
. Annals of Clinical and Translational Neurology 10:11, pages 1948-1971.
Crossref
Crossref
Manling Xie, Praveen N. Pallegar, Sebastian Parusel, Aivi T. Nguyen & Long-Jun Wu. (2023) Regulation of cortical hyperexcitability in amyotrophic lateral sclerosis: focusing on glial mechanisms. Molecular Neurodegeneration 18:1.
Crossref
Crossref
Aaron Izenberg. (2023) Amyotrophic Lateral Sclerosis and Other Motor Neuron Diseases. CONTINUUM: Lifelong Learning in Neurology 29:5, pages 1538-1563.
Crossref
Crossref
Akiko Yamamuro-Tanabe, Yasuhiro Kosuge, Yuki Ishimaru & Yasuhiro Yoshioka. (2023) Schwann cell derived-peroxiredoxin protects motor neurons against hydrogen peroxide-induced cell death in mouse motor neuron cell line NSC-34. Journal of Pharmacological Sciences 153:2, pages 73-83.
Crossref
Crossref
Anas Zakarya Nourelden, Ibrahim Kamal, Abdulrahman Ibrahim Hagrass, Abdelrahman G. Tawfik, Mahmoud M. Elhady, Ahmed Hashem Fathallah, Mona Muhe Eldeen Eshag & Mohamed Sayed Zaazouee. (2023) Safety and efficacy of edaravone in patients with amyotrophic lateral sclerosis: a systematic review and meta-analysis. Neurological Sciences 44:10, pages 3429-3442.
Crossref
Crossref
Daniel M. Wanner, Patrick M. Becker, Simon Suhr, Nick Wannenmacher, Slava Ziegler, Justin Herrmann, Felix Willig, Julia Gabler, Khushbu Jangid, Juliane Schmid, Andreas C. Hans, Wolfgang Frey, Biprajit Sarkar, Johannes Kästner & René Peters. (2023) Cooperative Lewis Acid‐1,2,3‐Triazolium‐Aryloxide Catalysis: Pyrazolone Addition to Nitroolefins as Entry to Diaminoamides. Angewandte Chemie International Edition 62:36.
Crossref
Crossref
Daniel M. Wanner, Patrick M. Becker, Simon Suhr, Nick Wannenmacher, Slava Ziegler, Justin Herrmann, Felix Willig, Julia Gabler, Khushbu Jangid, Juliane Schmid, Andreas C. Hans, Wolfgang Frey, Biprajit Sarkar, Johannes Kästner & René Peters. (2023) Kooperative Lewis‐Säure‐1,2,3‐Triazolium‐Aryloxid‐Katalyse: Addition von Pyrazolonen an Nitroolefine als Zugang zu Diaminoamiden. Angewandte Chemie 135:36.
Crossref
Crossref
Orion P. Keifer, Juanmarco Gutierrez, Mark T. Butt, Sarah D. Cramer, Raymond Bartus, Malu Tansey, Daniel Deaver, Alexandre Betourne & Nicholas M. Boulis. (2023) Spinal cord and brain concentrations of riluzole after oral and intrathecal administration: A potential new treatment route for amyotrophic lateral sclerosis. PLOS ONE 18:8, pages e0277718.
Crossref
Crossref
Taha Alqahtani, Sharada L. Deore, Anjali A. Kide, Bhavana A. Shende, Ritika Sharma, Rita Dadarao Chakole, Lalita S. Nemade, Nikita Kishor Kale, Sudarshana Borah, Savita Shrikant Deokar, Ashok Behera, Divya Dhawal Bhandari, Nikita Gaikwad, Abul Kalam Azad & Arabinda Ghosh. (2023) Mitochondrial dysfunction and oxidative stress in Alzheimer’s disease, and Parkinson’s disease, Huntington’s disease and Amyotrophic Lateral Sclerosis -An updated review. Mitochondrion 71, pages 83-92.
Crossref
Crossref
Shubadra Priyadarshini & Senda Ajroud-Driss. (2023) Update on ALS Treatment. Current Treatment Options in Neurology 25:7, pages 199-212.
Crossref
Crossref
Susanne Petri, Torsten Grehl, Julian Grosskreutz, Martin Hecht, Andreas Hermann, Sarah Jesse, Paul Lingor, Wolfgang Löscher, André Maier, Benedikt Schoser, Marcus Weber & Albert C. Ludolph. (2023) Guideline “Motor neuron diseases” of the German Society of Neurology (Deutsche Gesellschaft für Neurologie). Neurological Research and Practice 5:1.
Crossref
Crossref
Reza Boostani, Nahid Olfati, Hosein Shamshiri, Zanireh Salimi, Farzad Fatehi, Seyed Arya Hedjazi, Atefeh Fakharian, Majid Ghasemi, Ali Asghar Okhovat, Keivan Basiri, Bahram Haghi Ashtiani, Behnaz Ansari, Gholam Reza Raissi, Seyed Ahmadreza Khatoonabadi, Payam Sarraf, Sara Movahed, Akram Panahi, Bentolhoda Ziaadini, Mohammad Yazdchi, Jalal Bakhtiyari & Shahriar Nafissi. (2023) Iranian clinical practice guideline for amyotrophic lateral sclerosis. Frontiers in Neurology 14.
Crossref
Crossref
Satoru Morimoto, Shinichi Takahashi, Daisuke Ito, Yugaku Daté, Kensuke Okada, Chris Kato, Shiho Nakamura, Fumiko Ozawa, Chai Muh Chyi, Ayumi Nishiyama, Naoki Suzuki, Koki Fujimori, Tosho Kondo, Masaki Takao, Miwa Hirai, Yasuaki Kabe, Makoto Suematsu, Masahiro Jinzaki, Masashi Aoki, Yuto Fujiki, Yasunori Sato, Norihiro Suzuki, Jin Nakahara & Hideyuki Okano. (2023) Phase 1/2a clinical trial in ALS with ropinirole, a drug candidate identified by iPSC drug discovery. Cell Stem Cell 30:6, pages 766-780.e9.
Crossref
Crossref
Riya Ben Patel, Akhilesh Kumar Bajpai & Kavitha Thirumurugan. (2023) Differential Expression of MicroRNAs and Predicted Drug Target in Amyotrophic Lateral Sclerosis. Journal of Molecular Neuroscience 73:6, pages 375-390.
Crossref
Crossref
Laura Tzeplaeff, Sibylle Wilfling, Maria Viktoria Requardt & Meret Herdick. (2023) Current State and Future Directions in the Therapy of ALS. Cells 12:11, pages 1523.
Crossref
Crossref
Franziska T. Wunsch, Nils Metzler-Nolte, Carsten Theiss & Veronika Matschke. (2023) Defects in Glutathione System in an Animal Model of Amyotrophic Lateral Sclerosis. Antioxidants 12:5, pages 1014.
Crossref
Crossref
H Moola, A Govind, J R Eloff & A Van Blydenstein. (2023) Motor neuron disease presenting with acute hypercapnic respiratory failure. African Journal of Thoracic and Critical Care Medicine, pages 27-28.
Crossref
Crossref
A. Hesters & G. Bruneteau. (2023) Outils thérapeutiques dans la sclérose latérale amyotrophique : enfin du nouveau !. Pratique Neurologique - FMC 14:1, pages 55-60.
Crossref
Crossref
Dmitriy NikitinAnil N MakamKangho SuhAvery McKennaJosh J CarlsonMarina RichardsonDavid M RindSteven D Pearson. (2023) The effectiveness and value of AMX0035 and oral edaravone for amyotrophic lateral sclerosis: A summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council. Journal of Managed Care & Specialty Pharmacy 29:2, pages 216-221.
Crossref
Crossref
Jun Wang, Xin-Fu Zhou & Yan-Jiang Wang. (2023) Continuous antioxidant drug exposure: a bridge from ideal world to real world of therapy for amyotrophic lateral sclerosis. Life Medicine 2:1.
Crossref
Crossref
Angela Genge, Gary L. Pattee, Gen Sobue, Masashi Aoki, Hiide Yoshino, Philippe Couratier, Christian Lunetta, Susanne Petri, Daniel Selness, Sachin Bidani, Manabu Hirai, Takeshi Sakata, Alejandro Salah, Stephen Apple, Art Wamil, Alexander Kalin & Carlayne E. Jackson. (2022) Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment. Muscle & Nerve 67:2, pages 124-129.
Crossref
Crossref
Cassandra N. Dennys, Florence Roussel, Rochelle Rodrigo, Xiaojin Zhang, Andrea Sierra Delgado, Annalisa Hartlaub, Asya Saelim‐Ector, Will Ray, Sarah Heintzman, Ashley Fox, Stephen J. Kolb, Joseph Beckman, Maria Clara Franco & Kathrin Meyer. (2022)
CuATSM
effectively ameliorates
ALS
patient astrocyte‐mediated motor neuron toxicity in human in vitro models of amyotrophic lateral sclerosis
. Glia 71:2, pages 350-365.
Crossref
Crossref
Roland G. Huber, Swapnil Pandey, Deepak Chhangani, Diego E. Rincon‐Limas, Nathan P. Staff & Crystal Jing Jing Yeo. (2022)
Identification of potential pathways and biomarkers linked to progression in
ALS
. Annals of Clinical and Translational Neurology 10:2, pages 150-165.
Crossref
Crossref
Shotaro Haji, Koji Fujita, Ryosuke Oki, Yusuke Osaki, Ryosuke Miyamoto, Hiroyuki Morino, Seiichi Nagano, Naoki Atsuta, Yuki Kanazawa, Yuki Matsumoto, Atsuko Arisawa, Hisashi Kawai, Yasutaka Sato, Satoshi Sakaguchi, Kenta Yagi, Tatsuto Hamatani, Tatsuo Kagimura, Hiroaki Yanagawa, Hideki Mochizuki, Manabu Doyu, Gen Sobue, Masafumi Harada & Yuishin Izumi. (2023) An Exploratory Trial of EPI-589 in Amyotrophic Lateral Sclerosis (EPIC-ALS): Protocol for a Multicenter, Open-Labeled, 24-Week, Single-Group Study. JMIR Research Protocols 12, pages e42032.
Crossref
Crossref
Albert J. B. Lee, Tyler E. Kittel, Renaid B. Kim, Thao-Nguyen Bach, Tian Zhang & Cassie S. Mitchell. (2023) Comparing therapeutic modulators of the SOD1 G93A Amyotrophic Lateral Sclerosis mouse pathophysiology. Frontiers in Neuroscience 16.
Crossref
Crossref
Toru Yamashita, Yumiko Nakano, Ryo Sasaki, Koh Tadokoro, Yoshio Omote, Taijun Yunoki, Yuko Kawahara, Namiko Matsumoto, Yuki Taira, Chika Matsuoka, Ryuta Morihara & Koji Abe. (2023) Safety and Clinical Effects of a Muse Cell-Based Product in Patients With Amyotrophic Lateral Sclerosis: Results of a Phase 2 Clinical Trial. Cell Transplantation 32.
Crossref
Crossref
Pedro Soares, Catia Silva, Daniel Chavarria, Filomena S.G. Silva, Paulo J. Oliveira & Fernanda Borges. (2023) Drug discovery and amyotrophic lateral sclerosis: Emerging challenges and therapeutic opportunities. Ageing Research Reviews 83, pages 101790.
Crossref
Crossref
Luca Muzio, Alma Ghirelli, Federica Agosta & Gianvito Martino. 2023. Motor System Disorders, Part II: Spinal Cord, Neurodegenerative, and Cerebral Disorders and Treatment. Motor System Disorders, Part II: Spinal Cord, Neurodegenerative, and Cerebral Disorders and Treatment
523
537
.
Oleksandra Sirozh, Anabel Saez-Mas, Vanesa Lafarga & Oscar Fernandez-Capetillo. 2023. Encyclopedia of Cell Biology. Encyclopedia of Cell Biology
644
665
.
Mengxia Gao, Lingqun Zhu, Jingling Chang, Tianyu Cao, Lianying Song, Chunli Wen, Yi Chen, Yudi Zhuo & Fei Chen. (2022) Safety and Efficacy of Edaravone in Patients with Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-analysis. Clinical Drug Investigation 43:1, pages 1-11.
Crossref
Crossref
Hidetoshi Shimizu, Yukiko Nishimura, Youichi Shiide, Masaki Ueda, Shoko Yokota, Yuichiro Kato & Manabu Hirai. (2022) Edaravone Administered Orally and Via Nasogastric Tube in Healthy Adults: A Comparative Bioavailability Phase 1 Study. Clinical Pharmacology in Drug Development 12:1, pages 77-84.
Crossref
Crossref
Hidetoshi Shimizu, Yukiko Nishimura, Youichi Shiide, Makoto Akimoto, Hideaki Matsuda, Yuichiro Kato & Manabu Hirai. (2022) Food Effect Study to Assess the Impact on Edaravone Pharmacokinetic Profiles in Healthy Participants. Clinical Therapeutics 44:12, pages 1552-1565.
Crossref
Crossref
Jeremy M. Shefner, Richard Bedlack, Jinsy A. Andrews, James D. Berry, Robert Bowser, Robert Brown, Jonathan D. Glass, Nicholas J. Maragakis, Timothy M. Miller, Jeffrey D. Rothstein & Merit E. Cudkowicz. (2022) Amyotrophic Lateral Sclerosis Clinical Trials and Interpretation of Functional End Points and Fluid Biomarkers. JAMA Neurology 79:12, pages 1312.
Crossref
Crossref
Sherif M. Elbasiouny. (2022) Motoneuron excitability dysfunction in ALS: Pseudo‐mystery or authentic conundrum?. The Journal of Physiology 600:22, pages 4815-4825.
Crossref
Crossref
Fumihiro Takahashi, Osamu Kano, Yoshito Nagano, Takatomo Yoneoka, Sally Nelson & Yoshiteru Ushirogawa. (2022)
Associations between the
ALSFRS‐R
score and urate levels during 12 months of edaravone treatment for amyotrophic lateral sclerosis: Post hoc analysis of
ALSFRS‐R
scores in clinical studies
MCI186
‐16,
MCI186
‐17, and
MCI186
‐19
. Muscle & Nerve 66:5, pages 593-602.
Crossref
Crossref
Fumihiro Takahashi, Osamu Kano, Yoshito Nagano, Takatomo Yoneoka, Sally Nelson & Yoshiteru Ushirogawa. (2022)
Associations between urate levels and amyotrophic lateral sclerosis functional score with edaravone treatment: Post hoc analysis of studies
MCI186
‐16,
MCI186
‐17, and
MCI186
‐19
. Muscle & Nerve 66:5, pages 583-592.
Crossref
Crossref
Nick Wannenmacher, Martin Heberle, Xin Yu, Aysegül Demircan, Daniel M. Wanner, Camilla Pfeffer & René Peters. (2022) Diastereospecific Enantiodivergent Allylation of Pyrazolones as an Entry to β‐Aminoamides. Advanced Synthesis & Catalysis 364:19, pages 3396-3403.
Crossref
Crossref
Johannes Dorst & Angela Genge. (2022) Clinical studies in amyotrophic lateral sclerosis. Current Opinion in Neurology 35:5, pages 686-692.
Crossref
Crossref
Naoto Noda, Tatsuto Hamatani, Yuta Shibue, Takeshi Takagaki, Atsushi Kitamura, Miwa Haranaka, Yoichiro Ogama & Hiroyoshi Kakuyama. (2022) Phase 1 Study to Investigate the Safety, Tolerability, and Pharmacokinetics of EPI‐589 in Healthy Participants. Clinical Pharmacology in Drug Development 11:10, pages 1136-1146.
Crossref
Crossref
Morgan M. Highlander & Sherif M. Elbasiouny. (2022) Non-Invasive Transcutaneous Spinal DC Stimulation as a Neurorehabilitation ALS Therapy in Awake G93A Mice: The First Step to Clinical Translation. Bioengineering 9:9, pages 441.
Crossref
Crossref
Angela Genge, Benjamin Rix Brooks, Björn Oskarsson, Alexander Kalin, Ming Ji, Stephen Apple & Laura Bower. (2022) Analysis of the US Safety Data for Edaravone (Radicava®) From the Third Year After Launch. Drugs in R&D 22:3, pages 205-211.
Crossref
Crossref
Stephen A. Johnson, Ton Fang, Fabiola De Marchi, Dylan Neel, Donatienne Van Weehaeghe, James D. Berry & Sabrina Paganoni. (2022) Pharmacotherapy for Amyotrophic Lateral Sclerosis: A Review of Approved and Upcoming Agents. Drugs 82:13, pages 1367-1388.
Crossref
Crossref
Maya Junghans, Felix John, Hilal Cihankaya, Daniel Schliebs, Konstanze F. Winklhofer, Verian Bader, Johann Matschke, Carsten Theiss & Veronika Matschke. (2022) ROS scavengers decrease γH2ax spots in motor neuronal nuclei of ALS model mice in vitro. Frontiers in Cellular Neuroscience 16.
Crossref
Crossref
Bradley Roberts, Frances Theunissen, Francis L. Mastaglia, P. Anthony Akkari & Loren L. Flynn. (2022) Synucleinopathy in Amyotrophic Lateral Sclerosis: A Potential Avenue for Antisense Therapeutics?. International Journal of Molecular Sciences 23:16, pages 9364.
Crossref
Crossref
Anca Motataianu, Georgiana Serban, Laura Barcutean & Rodica Balasa. (2022) Oxidative Stress in Amyotrophic Lateral Sclerosis: Synergy of Genetic and Environmental Factors. International Journal of Molecular Sciences 23:16, pages 9339.
Crossref
Crossref
Zafer Sahin, Yağmur Özhan, Hande Sipahi, Sevde Nur Biltekin, Leyla Yurttaş, Barkin Berk & Şeref Demirayak. (2022) Novel benzofurane-pyrazole derivatives with anti-inflammatory, cyclooxygenase inhibitory and cytotoxicity evaluation. Zeitschrift für Naturforschung C 77:7-8, pages 279-285.
Crossref
Crossref
Christina N. Fournier. (2022) Considerations for Amyotrophic Lateral Sclerosis (ALS) Clinical Trial Design. Neurotherapeutics 19:4, pages 1180-1192.
Crossref
Crossref
Robert G. Miller, Rongzhen Zhang, Paige M. Bracci, Ari Azhir, Richard Barohn, Richard Bedlack, Michael Benatar, James D. Berry, Merit Cudkowicz, Edward J. Kasarskis, Hiroshi Mitsumoto, Georgios Manousakis, David Walk, Bjorn Oskarsson, Jeremy Shefner & Michael S. McGrath. (2022)
Phase
2B
randomized controlled trial of
NP001
in amyotrophic lateral sclerosis: Pre‐specified and post hoc analyses
. Muscle & Nerve 66:1, pages 39-49.
Crossref
Crossref
Eduardo J. Pérez-Torres, Irina Utkina-Sosunova, Vartika Mishra, Peter Barbuti, Mariangels De Planell-Saguer, Georgia Dermentzaki, Heather Geiger, Anna O. Basile, Nicolas Robine, Delphine Fagegaltier, Kristin A. Politi, Paola Rinchetti, Vernice Jackson-Lewis, Matthew Harms, Hemali Phatnani, Francesco Lotti, Serge Przedborski, Hemali Phatnani, Justin Kwan, Dhruv Sareen, James R. Broach, Zachary Simmons, Ximena Arcila-Londono, Edward B. Lee, Vivianna M. Van Deerlin, Neil A. Shneider, Ernest Fraenkel, Lyle W. Ostrow, Frank Baas, Noah Zaitlen, James D. Berry, Andrea Malaspina, Pietro Fratta, Gregory A. Cox, Leslie M. Thompson, Steve Finkbeiner, Efthimios Dardiotis, Timothy M. Miller, Siddharthan Chandran, Suvankar Pal, Eran Hornstein, Daniel J. MacGowan, Terry Heiman-Patterson, Molly G. Hammell, Nikolaos A. Patsopoulos, Oleg Butovsky, Joshua Dubnau, Avindra Nath, Robert Bowser, Matthew Harms, Eleonora Aronica, Mary Poss, Jennifer Phillips-Cremins, John Crary, Nazem Atassi, Dale J. Lange, Darius J. Adams, Leonidas Stefanis, Marc Gotkine, Robert H. Baloh, Suma Babu, Towfique Raj, Sabrina Paganoni, Ophir Shalem, Colin Smith, Bin Zhang, Brent Harris, Iris Broce, Vivian Drory, John Ravits, Corey McMillan, Vilas Menon, Lani Wu, Steven Altschuler, Yossef Lerner, Rita Sattler, Kendall Van Keuren-Jensen, Orit Rozenblatt-Rosen, Kerstin Lindblad-Toh, Katharine Nicholson, Peter Gregersen, Jeong-Ho Lee, Maze Therapeutics, Bristol-Myers Squibb, Pfizer, Sulev Kokos, Stephen Muljo & Bryan J. Traynor. (2022) Retromer dysfunction in amyotrophic lateral sclerosis. Proceedings of the National Academy of Sciences 119:26.
Crossref
Crossref
Benjamin Rix Brooks, Terry Heiman-Patterson, Martina Wiedau-Pazos, Shawn Liu, Jeffrey Zhang & Stephen Apple. (2022) Edaravone efficacy in amyotrophic lateral sclerosis with reduced forced vital capacity: Post-hoc analysis of Study 19 (MCI186-19) [clinical trial NCT01492686]. PLOS ONE 17:6, pages e0258614.
Crossref
Crossref
Sean-Patrick Riechers, Jelena Mojsilovic-Petrovic, Tayler B. Belton, Ram P. Chakrabarty, Mehraveh Garjani, Valentina Medvedeva, Casey Dalton, Yvette C. Wong, Navdeep S. Chandel, Gerald Dienel & Robert G. Kalb. (2022) Neurons undergo pathogenic metabolic reprogramming in models of familial ALS. Molecular Metabolism 60, pages 101468.
Crossref
Crossref
Paolo Tornese, Stefania Lalli, Antoniangela Cocco & Alberto Albanese. (2022) Review of disease-modifying drug trials in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery & Psychiatry 93:5, pages 521-529.
Crossref
Crossref
Lu Tang & Dongsheng Fan. (2022) Amyotrophic lateral sclerosis: new era, new challenges. The Lancet Neurology 21:5, pages 400-401.
Crossref
Crossref
Myrsini Chamakioti, Nikolaos Karantzelis & Stavros Taraviras. (2022) Advanced Gene-Targeting Therapies for Motor Neuron Diseases and Muscular Dystrophies. International Journal of Molecular Sciences 23:9, pages 4824.
Crossref
Crossref
Lu Yan, Min-Song Guo, Yue Zhang, Lu Yu, Jian-Ming Wu, Yong Tang, Wei Ai, Feng-Dan Zhu, Betty Yuen-Kwan Law, Qi Chen, Chong-Lin Yu, Vincent Kam-Wai Wong, Hua Li, Mao Li, Xiao-Gang Zhou, Da-Lian Qin & An-Guo Wu. (2022) Dietary Plant Polyphenols as the Potential Drugs in Neurodegenerative Diseases: Current Evidence, Advances, and Opportunities. Oxidative Medicine and Cellular Longevity 2022, pages 1-40.
Crossref
Crossref
Jia-Tong Li, Si-Qi Dong, Ting Qian, Wen-Bo Yang & Xiang-Jun Chen. (2022) Mouse Nerve Growth Factor Injection and Progression Rate in Patients With Amyotrophic Lateral Sclerosis: An Observational Study. Frontiers in Neurology 13.
Crossref
Crossref
Simon Witzel, André Maier, Robert Steinbach, Julian Grosskreutz, Jan C. Koch, Anastasia Sarikidi, Susanne Petri, René Günther, Joachim Wolf, Andreas Hermann, Johannes Prudlo, Isabell Cordts, Paul Lingor, Wolfgang N. Löscher, Zacharias Kohl, Tim Hagenacker, Christian Ruckes, Birgit Koch, Susanne Spittel, Kornelia Günther, Sebastian Michels, Johannes Dorst, Thomas Meyer & Albert C. Ludolph. (2022) Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis. JAMA Neurology 79:2, pages 121.
Crossref
Crossref
Jonathan D. Glass & Christina N. Fournier. (2022) Unintended Consequences of Approving Unproven Treatments—Hope, Hype, or Harm?. JAMA Neurology 79:2, pages 117.
Crossref
Crossref
Pasha Apontes. 2022. TDP-43 and Neurodegeneration. TDP-43 and Neurodegeneration
183
250
.
Sweta Shah, Marc Marie Dooms, Sofia Amaral-Garcia & Mariana Igoillo-Esteve. (2021) Current Drug Repurposing Strategies for Rare Neurodegenerative Disorders. Frontiers in Pharmacology 12.
Crossref
Crossref
Ammar Aljabri, Alhussain Halawani, Ghassan Bin Lajdam, Suhail Labban, Samah Alshehri & Razaz Felemban. (2021) The Safety and Efficacy of Stem Cell Therapy as an Emerging Therapy for ALS: A Systematic Review of Controlled Clinical Trials. Frontiers in Neurology 12.
Crossref
Crossref
Björn Oskarsson, Nicholas Maragakis, Richard S Bedlack, Namita Goyal, Jenny A Meyer, Angela Genge, Cynthia Bodkin, Samuel Maiser, Nathan Staff, Lorne Zinman, Nicholas Olney, John Turnbull, Benjamin Rix Brooks, Emelia Klonowski, Malath Makhay, Seiichi Yasui & Kazuko Matsuda. (2021) MN-166 (ibudilast) in amyotrophic lateral sclerosis in a Phase IIb/III study: COMBAT-ALS study design. Neurodegenerative Disease Management 11:6, pages 431-443.
Crossref
Crossref
Ismail Ibrahim Ismail, Fathi Massoud, Walaa Ahmed Kamel & Jasem Youssef Al-Hashel. (2020) Evaluation of clinical outcome and safety profile of edaravone in treatment of amyotrophic lateral sclerosis: a 72-week single-center experience. Acta Neurologica Belgica 121:6, pages 1591-1597.
Crossref
Crossref
C. Quarracino, M. Bendersky, R. Rey & G. E. Rodríguez. (2020) Logistics and safety of edaravone treatment for amyotrophic lateral sclerosis: experience in Argentina. Acta Neurologica Belgica 121:6, pages 1519-1523.
Crossref
Crossref
Gary W. Gallagher, Dustin Nowacek, Olivia Gutgsell & Brian C. Callaghan. (2021) Comparison of the United Kingdom and United States approaches to approval of new neuromuscular therapies. Muscle & Nerve 64:6, pages 641-650.
Crossref
Crossref
Yan-ni Zhou, You-hong Chen, Si-qi Dong, Wen-bo Yang, Ting Qian, Xiao-ni Liu, Qi Cheng, Jiu-cun Wang & Xiang-jun Chen. (2021) Role of Blood Neurofilaments in the Prognosis of Amyotrophic Lateral Sclerosis: A Meta-Analysis. Frontiers in Neurology 12.
Crossref
Crossref
Charis Wong, Maria Stavrou, Elizabeth Elliott, Jenna M Gregory, Nigel Leigh, Ashwin A Pinto, Timothy L Williams, Jeremy Chataway, Robert Swingler, Mahesh K B Parmar, Nigel Stallard, Christopher J Weir, Richard A Parker, Amina Chaouch, Hisham Hamdalla, John Ealing, George Gorrie, Ian Morrison, Callum Duncan, Peter Connelly, Francisco Javier Carod-Artal, Richard Davenport, Pablo Garcia Reitboeck, Aleksandar Radunovic, Venkataramanan Srinivasan, Jenny Preston, Arpan R Mehta, Danielle Leighton, Stella Glasmacher, Emily Beswick, Jill Williamson, Amy Stenson, Christine Weaver, Judith Newton, Dawn Lyle, Rachel Dakin, Malcolm Macleod, Suvankar Pal & Siddharthan Chandran. (2021) Clinical trials in amyotrophic lateral sclerosis: a systematic review and perspective. Brain Communications 3:4.
Crossref
Crossref
Hidetoshi Shimizu, Yukiko Nishimura, Youichi Shiide, Kaori Yoshida, Manabu Hirai, Munetomo Matsuda, Yoshinobu Nakamaru, Yuichiro Kato & Kazuoki Kondo. (2021) Bioequivalence Study of Oral Suspension and Intravenous Formulation of Edaravone in Healthy Adult Subjects. Clinical Pharmacology in Drug Development 10:10, pages 1188-1197.
Crossref
Crossref
Hidetoshi Shimizu, Yukiko Nishimura, Yoichi Shiide, Hideaki Matsuda, Makoto Akimoto, Munetomo Matsuda, Yoshinobu Nakamaru, Yuichiro Kato & Kazuoki Kondo. (2021) Evaluation of Pharmacokinetics, Safety, and Drug‐Drug Interactions of an Oral Suspension of Edaravone in Healthy Adults. Clinical Pharmacology in Drug Development 10:10, pages 1174-1187.
Crossref
Crossref
Aqsa Ullah, Mays Alani, Omar Chaudry, Afra Janarious, Nina Tsakadze, Michele Nunes, Umesh Sharma, Lourdes Benes-Lima, Elisa Marie Rossi, Carlyn Rodriguez-Nazario & Fabian Rossi. 2021. Updates in Sleep Neurology and Obstructive Sleep Apnea. Updates in Sleep Neurology and Obstructive Sleep Apnea.
J. Jiménez-Villegas, L. Ferraiuolo, R.J. Mead, P.J. Shaw, A. Cuadrado & A.I. Rojo. (2021) NRF2 as a therapeutic opportunity to impact in the molecular roadmap of ALS. Free Radical Biology and Medicine 173, pages 125-141.
Crossref
Crossref
Maximillian Taro William Lee, William Mahy & Mark David Rackham. (2021) The medicinal chemistry of mitochondrial dysfunction: a critical overview of efforts to modulate mitochondrial health. RSC Medicinal Chemistry 12:8, pages 1281-1311.
Crossref
Crossref
Xiaojiao Xu, Dingding Shen, Yining Gao, Qinming Zhou, You Ni, Huanyu Meng, Hongqin Shi, Weidong Le, Shengdi Chen & Sheng Chen. (2021) A perspective on therapies for amyotrophic lateral sclerosis: can disease progression be curbed?. Translational Neurodegeneration 10:1.
Crossref
Crossref
James BerryBenjamin Brooks, Angela GengeTerry Heiman-PattersonStanley AppelMichael BenatarRobert BowserMerit CudkowiczClifton GoochJeremy ShefnerJurjen WestraWendy AgneseCharlotte MerrillSally NelsonStephen Apple. (2021) Radicava/Edaravone Findings in Biomarkers From Amyotrophic Lateral Sclerosis (REFINE-ALS). Neurology Clinical Practice 11:4.
Crossref
Crossref
Heather M. Wilkins, Mazen M. Dimachkie & Abdulbaki Agbas. 2021. Amyotrophic Lateral Sclerosis. Amyotrophic Lateral Sclerosis
105
120
.
Hideki Houzen, Takahiro Kano, Kazuhiro Horiuchi, Masahiro Wakita, Azusa Nagai & Ichiro Yabe. (2021) Improved Long-Term Survival with Edaravone Therapy in Patients with Amyotrophic Lateral Sclerosis: A Retrospective Single-Center Study in Japan. Pharmaceuticals 14:8, pages 705.
Crossref
Crossref
Pavel Schischlevskij, Isabell Cordts, René Günther, Benjamin Stolte, Daniel Zeller, Carsten Schröter, Ute Weyen, Martin Regensburger, Joachim Wolf, Ilka Schneider, Andreas Hermann, Moritz Metelmann, Zacharias Kohl, Ralf A. Linker, Jan Christoph Koch, Claudia Stendel, Lars H. Müschen, Alma Osmanovic, Camilla Binz, Thomas Klopstock, Johannes Dorst, Albert C. Ludolph, Matthias Boentert, Tim Hagenacker, Marcus Deschauer, Paul Lingor, Susanne Petri & Olivia Schreiber-Katz. (2021) Informal Caregiving in Amyotrophic Lateral Sclerosis (ALS): A High Caregiver Burden and Drastic Consequences on Caregivers’ Lives. Brain Sciences 11:6, pages 748.
Crossref
Crossref
Alok Sharma, Hemangi Sane, Amruta Paranjape, Ritu Varghese, Vivek Nair, Hema Biju, Dhanashree Sawant, Nandini Gokulchandran & Prerna Badhe. (2021) Improved survival in amyotrophic lateral sclerosis patients following autologous bone marrow mononuclear cell therapy: a long term 10-year retrospective study. Journal of Neurorestoratology 9:2, pages 117-136.
Crossref
Crossref
Kaoru Ishizaki, Kenta Yoshimura, Kengo Yoshida, Masao Matsuda, Yutaka Kawaguchi, Satoshi Yuki & Gen Sobue. (2021) Real‐world safety of the novel, free radical scavenger edaravone for amyotrophic lateral sclerosis patients: Data from the post‐marketing surveillance SUNRISE Japan. Neurology and Clinical Neuroscience 9:3, pages 223-229.
Crossref
Crossref
Audrey Labarre & Alex Parker. 2021. Spectrums of Amyotrophic Lateral Sclerosis. Spectrums of Amyotrophic Lateral Sclerosis
81
103
.
Jessica R. Morrice, Michael Kuo & Christopher A. Shaw. 2021. Spectrums of Amyotrophic Lateral Sclerosis. Spectrums of Amyotrophic Lateral Sclerosis
181
199
.
Toru Yamashita, Yoshihiro Kushida, Koji Abe & Mari Dezawa. (2021) Non-Tumorigenic Pluripotent Reparative Muse Cells Provide a New Therapeutic Approach for Neurologic Diseases. Cells 10:4, pages 961.
Crossref
Crossref
Zaynab Shakkour, Hawraa Issa, Helene Ismail, Ohanes Ashekyan, Karl John Habashy, Leila Nasrallah, Hussam Jourdi, Eva Hamade, Stefania Mondello, Mirna Sabra, Kazem Zibara & Firas Kobeissy. (2021) Drug Repurposing: Promises of Edaravone Target Drug in Traumatic Brain Injury. Current Medicinal Chemistry 28:12, pages 2369-2391.
Crossref
Crossref
Cynthia Morata-Tarifa, Garikoitz Azkona, Jonathan Glass, Letizia Mazzini & Rosario Sanchez-Pernaute. (2021) Looking backward to move forward: a meta-analysis of stem cell therapy in amyotrophic lateral sclerosis. npj Regenerative Medicine 6:1.
Crossref
Crossref
Matt Keon, Benjamin Musrie, Marcel Dinger, Samuel E. Brennan, Jerran Santos & Nitin K. Saksena. (2021) Destination Amyotrophic Lateral Sclerosis. Frontiers in Neurology 12.
Crossref
Crossref
Tara Peseschkian, Isabell Cordts, René Günther, Benjamin Stolte, Daniel Zeller, Carsten Schröter, Ute Weyen, Martin Regensburger, Joachim Wolf, Ilka Schneider, Andreas Hermann, Moritz Metelmann, Zacharias Kohl, Ralf A. Linker, Jan Christoph Koch, Boriana Büchner, Ulrike Weiland, Erik Schönfelder, Felix Heinrich, Alma Osmanovic, Thomas Klopstock, Johannes Dorst, Albert C. Ludolph, Matthias Boentert, Tim Hagenacker, Marcus Deschauer, Paul Lingor, Susanne Petri & Olivia Schreiber-Katz. (2021) A Nation-Wide, Multi-Center Study on the Quality of Life of ALS Patients in Germany. Brain Sciences 11:3, pages 372.
Crossref
Crossref
Masamichi Ikawa, Hidehiko Okazawa & Makoto Yoneda. (2021) Molecular imaging for mitochondrial metabolism and oxidative stress in mitochondrial diseases and neurodegenerative disorders. Biochimica et Biophysica Acta (BBA) - General Subjects 1865:3, pages 129832.
Crossref
Crossref
Cyril Jones Jagaraj, Sonam Parakh & Julie D. Atkin. (2021) Emerging Evidence Highlighting the Importance of Redox Dysregulation in the Pathogenesis of Amyotrophic Lateral Sclerosis (ALS). Frontiers in Cellular Neuroscience 14.
Crossref
Crossref
Courtney M. Clark, Rosemary M. Clark, Joshua A. Hoyle & Tracey C. Dickson. (2020) Pathogenic or protective? Neuropeptide Y in amyotrophic lateral sclerosis. Journal of Neurochemistry 156:3, pages 273-289.
Crossref
Crossref
Asako Kakimoto, Masatoshi Ishizaki, Hidetsugu Ueyama, Yasushi Maeda & Mitsuharu Ueda. (2021) Renal function in amyotrophic lateral sclerosis patients on long-term treatment with edaravone. Medicine 100:21, pages e26127.
Crossref
Crossref
Danielle Beaulieu, Albert A. Taylor, Dustin Pierce, Jonavelle Cuerdo, Mark Schactman, Mike Keymer & David L. Ennist. 2021. Neurotherapeutics in the Era of Translational Medicine. Neurotherapeutics in the Era of Translational Medicine
333
366
.
John D. Lee, Saman Heshmat, Susan Heggie, Kathryn A. Thorpe, Pamela A. McCombe & Robert D. Henderson. (2020) Clinical and electrophysiological examination of pinch strength in patients with amyotrophic lateral sclerosis. Muscle & Nerve 63:1, pages 108-113.
Crossref
Crossref
Sabrina Paganoni, Suzanne Hendrix, Samuel P. Dickson, Newman Knowlton, Eric A. Macklin, James D. Berry, Michael A. Elliott, Samuel Maiser, Chafic Karam, James B. Caress, Margaret Ayo Owegi, Adam Quick, James Wymer, Stephen A. Goutman, Daragh Heitzman, Terry D. Heiman‐Patterson, Carlayne E. Jackson, Colin Quinn, Jeffrey D. Rothstein, Edward J. Kasarskis, Jonathan Katz, Liberty Jenkins, Shafeeq Ladha, Timothy M. Miller, Stephen N. Scelsa, Tuan H. Vu, Christina N. Fournier, Jonathan D. Glass, Kristin M. Johnson, Andrea Swenson, Namita A. Goyal, Gary L. Pattee, Patricia L. Andres, Suma Babu, Marianne Chase, Derek Dagostino, Meghan Hall, Gale Kittle, Matthew Eydinov, Michelle McGovern, Joseph Ostrow, Lindsay Pothier, Rebecca Randall, Jeremy M. Shefner, Alexander V. Sherman, Maria E. St Pierre, Eric Tustison, Prasha Vigneswaran, Jason Walker, Hong Yu, James Chan, Janet Wittes, Zi‐Fan Yu, Joshua Cohen, Justin Klee, Kent Leslie, Rudolph E. Tanzi, Walter Gilbert, Patrick D. Yeramian, David Schoenfeld & Merit E. Cudkowicz. (2020)
Long‐term survival of participants in the
CENTAUR
trial of sodium phenylbutyrate‐taurursodiol in
amyotrophic lateral sclerosis
. Muscle & Nerve 63:1, pages 31-39.
Crossref
Crossref
Erik Schönfelder, Alma Osmanovic, Lars Hendrik Müschen, Susanne Petri & Olivia Schreiber-Katz. (2020) Costs of illness in amyotrophic lateral sclerosis (ALS): a cross-sectional survey in Germany. Orphanet Journal of Rare Diseases 15:1.
Crossref
Crossref
Jessica A. Cooksey & Amen Sergew. (2020) Noninvasive Ventilation in Amyotrophic Lateral Sclerosis. Sleep Medicine Clinics 15:4, pages 527-538.
Crossref
Crossref
Teresa Cunha-Oliveira, Liliana Montezinho, Catarina Mendes, Omidreza Firuzi, Luciano Saso, Paulo J. Oliveira & Filomena S. G. Silva. (2020) Oxidative Stress in Amyotrophic Lateral Sclerosis: Pathophysiology and Opportunities for Pharmacological Intervention. Oxidative Medicine and Cellular Longevity 2020, pages 1-29.
Crossref
Crossref
Luke McAlary, Yee Lian Chew, Jeremy Stephen Lum, Nicholas John Geraghty, Justin John Yerbury & Neil R. Cashman. (2020) Amyotrophic Lateral Sclerosis: Proteins, Proteostasis, Prions, and Promises. Frontiers in Cellular Neuroscience 14.
Crossref
Crossref
Christian Lunetta, Cristina Moglia, Andrea Lizio, Claudia Caponnetto, Raffaele Dubbioso, Fabio Giannini, Sabrina Matà, Letizia Mazzini, Mario Sabatelli, Gabriele Siciliano, Isabella Laura Simone, Gianni Sorarù, Antonella Toriello, Francesca Trojsi, Marcella Vedovello, Fabrizio D’Ovidio, Massimo Filippi & Andrea Calvo. (2020) The Italian multicenter experience with edaravone in amyotrophic lateral sclerosis. Journal of Neurology 267:11, pages 3258-3267.
Crossref
Crossref
Gabrielle Fortier, Zoé Butti & Shunmoogum A. Patten. (2020) Modelling C9orf72-Related Amyotrophic Lateral Sclerosis in Zebrafish. Biomedicines 8:10, pages 440.
Crossref
Crossref
So Yoen Choi, Ju-Hyun Lee, Ah-Young Chung, Youhwa Jo, Joo-ho Shin, Hae-Chul Park, Hyun Kim, Rodrigo Lopez-Gonzalez, Jae Ryun Ryu & Woong Sun. (2020) Prevention of mitochondrial impairment by inhibition of protein phosphatase 1 activity in amyotrophic lateral sclerosis. Cell Death & Disease 11:10.
Crossref
Crossref
Juan Fernando Ortiz, Sawleha Arshi Khan, Amr Salem, Zayar Lin, Zafar Iqbal & Nusrat Jahan. (2020) Post-Marketing Experience of Edaravone in Amyotrophic Lateral Sclerosis: A Clinical Perspective and Comparison With the Clinical Trials of the Drug. Cureus.
Crossref
Crossref
Helene Ismail, Zaynab Shakkour, Maha Tabet, Samar Abdelhady, Abir Kobaisi, Reem Abedi, Leila Nasrallah, Gianfranco Pintus, Yusra Al-Dhaheri, Stefania Mondello, Riyad El-Khoury, Ali H. Eid, Firas Kobeissy & Johnny Salameh. (2020) Traumatic Brain Injury: Oxidative Stress and Novel Anti-Oxidants Such as Mitoquinone and Edaravone. Antioxidants 9:10, pages 943.
Crossref
Crossref
M. A Mukhamedyarov, E. O Petukhova, I. I Salafutdinov, M. S Kuznetsov, Z. Z Safiullov, R. R Islamov & A. L Zefirov. (2020) Analysis of efficacy of combined therapy of amyotrophic lateral sclerosis in mSOD1 transgenic mice model. Genes & Cells 15:3, pages 55-58.
Crossref
Crossref
Satoshi Yuki, Kaoru Ishizaki, Hanami Yoshioka, Hidekazu Nakamura, Manabu Hirai & Gen Sobue. (2020) Baseline characteristics of patients from ongoing post‐marketing surveillance, evaluating the real‐world efficacy and safety of edaravone, a novel, free radical scavenger, for amyotrophic lateral sclerosis patients in Japan (SUNRISE Japan). Neurology and Clinical Neuroscience 8:5, pages 261-269.
Crossref
Crossref
Kangsa Amporndanai, Michael Rogers, Seiji Watanabe, Koji Yamanaka, Paul M. O'Neill & S. Samar Hasnain. (2020) Novel Selenium-based compounds with therapeutic potential for SOD1-linked amyotrophic lateral sclerosis. eBioMedicine 59, pages 102980.
Crossref
Crossref
Yasuyuki Ohta, Toru Yamashita, Emi Nomura, Nozomi Hishikawa, Ken Ikegami, Yosuke Osakada, Namiko Matsumoto, Yuko Kawahara, Taijun Yunoki, Yoshiaki Takahashi, Motonori Takamiya, Koh Tadokoro, Ryo Sasaki, Yumiko Nakano, Keiichiro Tsunoda, Kota Sato, Yoshio Omote, Mami Takemoto & Koji Abe. (2020) Improvement of a decreased anti-oxidative activity by edaravone in amyotrophic lateral sclerosis patients. Journal of the Neurological Sciences 415, pages 116906.
Crossref
Crossref
Namita A. Goyal, James D. Berry, Anthony Windebank, Nathan P. Staff, Nicholas J. Maragakis, Leonard H. van den Berg, Angela Genge, Robert Miller, Robert H. Baloh, Ralph Kern, Yael Gothelf, Chaim Lebovits & Merit Cudkowicz. (2020) Addressing heterogeneity in amyotrophic lateral sclerosis CLINICAL TRIALS. Muscle & Nerve 62:2, pages 156-166.
Crossref
Crossref
Ruaridh Cameron Smail & Neil Simon. (2020) Clinical Controversies in Amyotrophic Lateral Sclerosis. EMJ Neurology, pages 80-92.
Crossref
Crossref
Chihiro Kawano, Yurika Isozaki, Ayumi Nakagawa, Takeshi Hirayama, Kazutoshi Nishiyama & Masakazu Kuroyama. (2020) Liver Injury Risk Factors in Amyotrophic Lateral Sclerosis Patients Treated with RiluzoleLiver Injury Risk Factors in Amyotrophic Lateral Sclerosis Patients Treated with Riluzole. YAKUGAKU ZASSHI 140:7, pages 923-928.
Crossref
Crossref
Fen Huang, Yuda Zhu, Jennifer Hsiao‐Nakamoto, Xinyan Tang, Jason C. Dugas, Miriam Moscovitch‐Lopatin, Jonathan D. Glass, Robert H. BrownJrJr, Shafeeq S. Ladha, David Lacomis, Jeffrey M. Harris, Kimberly Scearce‐Levie, Carole Ho, Robert Bowser & James D. Berry. (2020) Longitudinal biomarkers in amyotrophic lateral sclerosis. Annals of Clinical and Translational Neurology 7:7, pages 1103-1116.
Crossref
Crossref
Snežana Spasić, Aleksandra Nikolić-Kokić, Srđan Miletić, Zorana Oreščanin-Dušić, Mihajlo B. Spasić, Duško Blagojević & Zorica Stević. (2020) Edaravone May Prevent Ferroptosis in ALS. Current Drug Targets 21:8, pages 776-780.
Crossref
Crossref
Zeynep I. Gunes, Vanessa W. Y. Kan, XiaoQian Ye & Sabine Liebscher. (2020) Exciting Complexity: The Role of Motor Circuit Elements in ALS Pathophysiology. Frontiers in Neuroscience 14.
Crossref
Crossref
Elyse A. EverettElizabeth PedowitzSamuel MaiserJoss CohenJessica BesbrisAmbereen K. MehtaLuqi ChiChristopher A. Jones. (2020) Top Ten Tips Palliative Care Clinicians Should Know About Amyotrophic Lateral Sclerosis. Journal of Palliative Medicine 23:6, pages 842-847.
Crossref
Crossref
Adriano Chiò, Letizia Mazzini & Gabriele Mora. (2020) Disease-modifying therapies in amyotrophic lateral sclerosis. Neuropharmacology 167, pages 107986.
Crossref
Crossref
Jana Janssens, Yannick Vermeiren, Martijn van Faassen, Claude van der Ley, Ido P. Kema & Peter P. De Deyn. (2020) Monoaminergic and Kynurenergic Characterization of Frontotemporal Dementia and Amyotrophic Lateral Sclerosis in Cerebrospinal Fluid and Serum. Neurochemical Research 45:5, pages 1191-1201.
Crossref
Crossref
S.N. Suresh, Anushka Chakravorty, Mridhula Giridharan, Lakshmi Garimella & Ravi Manjithaya. (2020) Pharmacological Tools to Modulate Autophagy in Neurodegenerative Diseases. Journal of Molecular Biology 432:8, pages 2822-2842.
Crossref
Crossref
Aristidis S. Veskoukis, Aristidis Tsatsakis & Demetrios Kouretas. (2020) Approaching reactive species in the frame of their clinical significance: A toxicological appraisal. Food and Chemical Toxicology 138, pages 111206.
Crossref
Crossref
Koh Tadokoro, Yasuyuki Ohta, Haruhiko Inufusa, Alan Foo Nyuk Loon & Koji Abe. (2020) Prevention of Cognitive Decline in Alzheimer’s Disease by Novel Antioxidative Supplements. International Journal of Molecular Sciences 21:6, pages 1974.
Crossref
Crossref
Alok Patel, Fiona Lynch & Starane A. Shepherd. (2020) Newer Immunotherapies for the Treatment of Acute Neuromuscular Disease in the Critical Care Unit. Current Treatment Options in Neurology 22:3.
Crossref
Crossref
Sandra Carrera-Juliá, Mari Luz Moreno, Carlos Barrios, Jose Enrique de la Rubia Ortí & Eraci Drehmer. (2020) Antioxidant Alternatives in the Treatment of Amyotrophic Lateral Sclerosis: A Comprehensive Review. Frontiers in Physiology 11.
Crossref
Crossref
Veronica Laos, Dezmond Bishop, Christian A. Lang, Nicole M. Marsh, Kristi Lazar Cantrell, Steven K. Buratto, Ambuj K. Singh & Michael T. Bowers. (2019)
Modulating ALS-Related Amyloidogenic TDP-43
307–319
Oligomeric Aggregates with Computationally Derived Therapeutic Molecules
. Biochemistry 59:4, pages 499-508.
Crossref
Crossref
Tereza Filipi, Zuzana Hermanova, Jana Tureckova, Ondrej Vanatko & Miroslava Anderova. (2020) Glial Cells—The Strategic Targets in Amyotrophic Lateral Sclerosis Treatment. Journal of Clinical Medicine 9:1, pages 261.
Crossref
Crossref
S Fadilah Abdul Wahid, Zhe Kang Law, Nor Azimah Ismail & Nai Ming Lai. (2019) Cell-based therapies for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews 2019:12.
Crossref
Crossref
Rita Mejzini, Loren L. Flynn, Ianthe L. Pitout, Sue Fletcher, Steve D. Wilton & P. Anthony Akkari. (2019) ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now?. Frontiers in Neuroscience 13.
Crossref
Crossref
Satoru Morimoto, Shinichi Takahashi, Komei Fukushima, Hideyuki Saya, Norihiro Suzuki, Masashi Aoki, Hideyuki Okano & Jin Nakahara. (2019) Ropinirole hydrochloride remedy for amyotrophic lateral sclerosis – Protocol for a randomized, double-blind, placebo-controlled, single-center, and open-label continuation phase I/IIa clinical trial (ROPALS trial). Regenerative Therapy 11, pages 143-166.
Crossref
Crossref
Daisuke Ito, Atsushi Hashizume, Yasuhiro Hijikata, Shinichiro Yamada, Yohei Iguchi, Madoka Iida, Yoshiyuki Kishimoto, Hideyuki Moriyoshi, Akihiro Hirakawa & Masahisa Katsuno. (2019) Elevated serum creatine kinase in the early stage of sporadic amyotrophic lateral sclerosis. Journal of Neurology 266:12, pages 2952-2961.
Crossref
Crossref
Jue Wang & Sheng Luo. (2018) Joint modeling of multiple repeated measures and survival data using multidimensional latent trait linear mixed model. Statistical Methods in Medical Research 28:10-11, pages 3392-3403.
Crossref
Crossref
Jingwei Shang, Toru Yamashita, Feng Tian, Xianghong Li, Xia Liu, Xiaowen Shi, Yumiko Nakano, Keiichiro Tsunoda, Emi Nomura, Ryo Sasaki, Koh Tadokoro, Kota Sato, Mami Takemoto, Nozomi Hishikawa, Yasuyuki Ohta & Koji Abe. (2019) Chronic cerebral hypoperfusion alters amyloid-β transport related proteins in the cortical blood vessels of Alzheimer’s disease model mouse. Brain Research 1723, pages 146379.
Crossref
Crossref
Lana M. Chahine, Andrew Siderowf, Janel Barnes, Nicholas Seedorff, Chelsea Caspell-Garcia, Tanya Simuni, Christopher S. Coffey, Douglas Galasko, Brit Mollenhauer, Vanessa Arnedo, Nichole Daegele, Mark Frasier, Caroline Tanner, Karl Kieburtz & Kenneth Marek. (2019) Predicting Progression in Parkinson’s Disease Using Baseline and 1-Year Change Measures. Journal of Parkinson's Disease 9:4, pages 665-679.
Crossref
Crossref
David Alan Schoenfeld, Dianne M Finkelstein, Eric Macklin, Neta Zach, David L Ennist, Albert A Taylor & Nazem Atassi. (2019) Design and analysis of a clinical trial using previous trials as historical control. Clinical Trials 16:5, pages 531-538.
Crossref
Crossref
Laura Rué, Mieke Timmers, Annette Lenaerts, Silke Smolders, Lindsay Poppe, Antina de Boer, Ludo Van Den Bosch, Philip Van Damme, Wim Robberecht & Robin Lemmens. (2019) Reducing EphA4 before disease onset does not affect survival in a mouse model of Amyotrophic Lateral Sclerosis. Scientific Reports 9:1.
Crossref
Crossref
Marisa Cappella, Chiara Ciotti, Mathilde Cohen-Tannoudji & Maria Grazia Biferi. (2019) Gene Therapy for ALS—A Perspective. International Journal of Molecular Sciences 20:18, pages 4388.
Crossref
Crossref
Andrea Fortuna, Matteo Gizzi, Luca Bello, Ilaria Martinelli, Cinzia Bertolin, Elena Pegoraro, Maurizio Corbetta & Gianni Sorarù. (2019) Safety and efficacy of edaravone compared to historical controls in patients with amyotrophic lateral sclerosis from North-Eastern Italy. Journal of the Neurological Sciences 404, pages 47-51.
Crossref
Crossref
Jonu Pradhan, Peter G. Noakes & Mark C. Bellingham. (2019) The Role of Altered BDNF/TrkB Signaling in Amyotrophic Lateral Sclerosis. Frontiers in Cellular Neuroscience 13.
Crossref
Crossref
Bhavesh D. Kevadiya, Brendan M. Ottemann, Midhun Ben Thomas, Insiya Mukadam, Saumya Nigam, JoEllyn McMillan, Santhi Gorantla, Tatiana K. Bronich, Benson Edagwa & Howard E. Gendelman. (2019) Neurotheranostics as personalized medicines. Advanced Drug Delivery Reviews 148, pages 252-289.
Crossref
Crossref
Jhan-Jie Peng, Shih-Han Lin, Yu-Tzu Liu, Hsin-Chieh Lin, Tsai-Ning Li & Chi-Kuang Yao. (2019) A circuit-dependent ROS feedback loop mediates glutamate excitotoxicity to sculpt the Drosophila motor system. eLife 8.
Crossref
Crossref
Gavin Pharaoh, Kavithalakshmi Sataranatarajan, Kaitlyn Street, Shauna Hill, Jake Gregston, Bumsoo Ahn, Caroline Kinter, Michael Kinter & Holly Van Remmen. (2019) Metabolic and Stress Response Changes Precede Disease Onset in the Spinal Cord of Mutant SOD1 ALS Mice. Frontiers in Neuroscience 13.
Crossref
Crossref
Yasuyuki Ohta, Emi Nomura, Jingwei Shang, Tian Feng, Yong Huang, Xia Liu, Xiaowen Shi, Yumiko Nakano, Nozomi Hishikawa, Kota Sato, Mami Takemoto, Toru Yamashita & Koji Abe. (2018) Enhanced oxidative stress and the treatment by edaravone in mice model of amyotrophic lateral sclerosis. Journal of Neuroscience Research 97:5, pages 607-619.
Crossref
Crossref
William Huynh, Thanuja Dharmadasa, Smriti Agarwal, Jashelle Caga & Matthew C. Kiernan. 2019. Degenerative Disorders of the Brain. Degenerative Disorders of the Brain
199
228
.
Simon Witzel & Albert Ludolph. (2019) Amyotrophe Lateralsklerose früh erkennen und behandeln. DNP - Der Neurologe & Psychiater 20:2, pages 56-68.
Crossref
Crossref
Manoj Kumar Jaiswal. (2018) Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs. Medicinal Research Reviews 39:2, pages 733-748.
Crossref
Crossref
Kerry L. Walker, Miriam J. Rodrigues, Beth Watson, Claire Reilly, Emma L. Scotter, Heather Brunton, Janet Turnbull & Richard H. Roxburgh. (2019) Establishment and 12-month progress of the New Zealand Motor Neurone Disease Registry. Journal of Clinical Neuroscience 60, pages 7-11.
Crossref
Crossref
Linting Luo, Zhibin Song, Xiaoqiang Li, Huiwang, Yaqing Zeng, Qinwang, Meiqi & Jianli He. (2018) Efficacy and safety of edaravone in treatment of amyotrophic lateral sclerosis—a systematic review and meta-analysis. Neurological Sciences 40:2, pages 235-241.
Crossref
Crossref
Zoe Butti & Shunmoogum A. Patten. (2019) RNA Dysregulation in Amyotrophic Lateral Sclerosis. Frontiers in Genetics 9.
Crossref
Crossref
Seyed A. Safavynia & Peter A. Goldstein. (2019) The Role of Neuroinflammation in Postoperative Cognitive Dysfunction: Moving From Hypothesis to Treatment. Frontiers in Psychiatry 9.
Crossref
Crossref
Shivangi Garg, Dinesh Chaudhari, PushpendraNath Renjen, Anjali Mishra, Abhas Kumar & Rajendra Pradhan. (2019) Edaravone: A new hope for patients with amyotrophic lateral sclerosis. Apollo Medicine 16:3, pages 157.
Crossref
Crossref
Georgia Dermentzaki, Kristin A. Politi, Lei Lu, Vartika Mishra, Eduardo J. Pérez-Torres, Alexander A. Sosunov, Guy M. McKhannIIII, Francesco Lotti, Neil A. Shneider & Serge Przedborski. (2019)
Deletion of
Ripk3
Prevents Motor Neuron Death
In Vitro
but not
In Vivo
. eneuro 6:1, pages ENEURO.0308-18.2018.
Crossref
Crossref
Alison E. Mungenast, Rebecca Aron, James D. White, Daniel F. Tardiff & Waseem K. Raja. 2019. Microfluidic Cell Culture Systems. Microfluidic Cell Culture Systems
249
296
.
Stephen Morgan, Stephanie Duguez & William Duddy. (2018) Personalized Medicine and Molecular Interaction Networks in Amyotrophic Lateral Sclerosis (ALS): Current Knowledge. Journal of Personalized Medicine 8:4, pages 44.
Crossref
Crossref
Ligia Akemi Kiyuna, Rudá Prestes e Albuquerque, Che-Hong Chen, Daria Mochly-Rosen & Julio Cesar Batista Ferreira. (2018) Targeting mitochondrial dysfunction and oxidative stress in heart failure: Challenges and opportunities. Free Radical Biology and Medicine 129, pages 155-168.
Crossref
Crossref
Rocio Garcia-Santibanez, Matthew Burford & Robert C. Bucelli. (2018) Hereditary Motor Neuropathies and Amyotrophic Lateral Sclerosis: a Molecular and Clinical Update. Current Neurology and Neuroscience Reports 18:12.
Crossref
Crossref
Björn Oskarsson, Tania F. Gendron & Nathan P. Staff. (2018) Amyotrophic Lateral Sclerosis: An Update for 2018. Mayo Clinic Proceedings 93:11, pages 1617-1628.
Crossref
Crossref
Displaying 200 of 247 citing articles. Use the download link below to view the full list of citing articles.
Download full citations list